"ADP-ribosyl Cyclase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
| Descriptor ID |
D051997
|
| MeSH Number(s) |
D08.811.277.450.430.400.060.500 D12.776.543.550.045
|
| Concept/Terms |
ADP-ribosyl Cyclase 1- ADP-ribosyl Cyclase 1
- 1, ADP-ribosyl Cyclase
- ADP ribosyl Cyclase 1
- Cyclase 1, ADP-ribosyl
- T10 Antigen
- Antigen, T10
- NIM-R5 Antigen
- NIM R5 Antigen
- CD38 Antigens
- ADPR Cyclase T10
- Cyclase T10, ADPR
- Acute Lymphoblastic Leukemia Cells Antigen CD38
- Lymphocyte Differentiation Antigen CD38
- Antigens, CD38
- CD38 Antigen
- ADPR Cyclase CD38
- CD38, ADPR Cyclase
- Cyclase CD38, ADPR
|
Below are MeSH descriptors whose meaning is more general than "ADP-ribosyl Cyclase 1".
Below are MeSH descriptors whose meaning is more specific than "ADP-ribosyl Cyclase 1".
This graph shows the total number of publications written about "ADP-ribosyl Cyclase 1" by people in this website by year, and whether "ADP-ribosyl Cyclase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 3 | 9 | 12 |
| 2018 | 1 | 6 | 7 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "ADP-ribosyl Cyclase 1" by people in Profiles.
-
Chronic Immune Activation and CD4+ T Cell Lymphopenia in Healthy African Individuals: Perspectives for SARS-CoV-2 Vaccine Efficacy. Front Immunol. 2021; 12:693269.
-
Endolysosomal Ca2+ signaling in cardiovascular health and disease. Int Rev Cell Mol Biol. 2021; 363:203-269.
-
Immunological and inflammatory profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. Int Immunopharmacol. 2021 Aug; 97:107685.
-
CD38 in the age of COVID-19: a medical perspective. Physiol Rev. 2021 10 01; 101(4):1457-1486.
-
T Cell Phenotyping in Individuals Hospitalized with COVID-19. J Immunol. 2021 04 01; 206(7):1478-1482.
-
Dynamic changes in monocytes subsets in COVID-19 patients. Hum Immunol. 2021 Mar; 82(3):170-176.
-
Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset. Front Immunol. 2020; 11:596553.
-
COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity. Med Hypotheses. 2020 Nov; 144:110044.
-
Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia. Chin Med J (Engl). 2019 Mar 05; 132(5):525-533.
-
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. Front Immunol. 2018; 9:2616.